300676 Stock Overview
Provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BGI Genomics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥45.75 |
| 52 Week High | CN¥56.89 |
| 52 Week Low | CN¥33.00 |
| Beta | 0.71 |
| 1 Month Change | -2.87% |
| 3 Month Change | 33.03% |
| 1 Year Change | -2.87% |
| 3 Year Change | -48.57% |
| 5 Year Change | -30.22% |
| Change since IPO | 132.94% |
Recent News & Updates
Is BGI Genomics (SZSE:300676) Using Too Much Debt?
Oct 22
BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 31%
Oct 01Recent updates
Is BGI Genomics (SZSE:300676) Using Too Much Debt?
Oct 22BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 31%
Oct 01Is BGI Genomics (SZSE:300676) A Risky Investment?
Jul 15Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S
May 22BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings
Apr 21Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly
Mar 25Shareholder Returns
| 300676 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.6% | -4.9% | -3.5% |
| 1Y | -2.9% | -17.6% | 10.9% |
Return vs Industry: 300676 exceeded the CN Biotechs industry which returned -17.6% over the past year.
Return vs Market: 300676 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 300676 volatility | |
|---|---|
| 300676 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300676 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300676's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 3,752 | Lijian Zhao | www.bgi.com |
BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2.
BGI Genomics Co., Ltd. Fundamentals Summary
| 300676 fundamental statistics | |
|---|---|
| Market cap | CN¥17.45b |
| Earnings (TTM) | -CN¥101.62m |
| Revenue (TTM) | CN¥4.03b |
4.3x
P/S Ratio-171.7x
P/E RatioIs 300676 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300676 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.03b |
| Cost of Revenue | CN¥2.12b |
| Gross Profit | CN¥1.91b |
| Other Expenses | CN¥2.01b |
| Earnings | -CN¥101.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 47.30% |
| Net Profit Margin | -2.52% |
| Debt/Equity Ratio | 3.5% |
How did 300676 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield-40%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 10:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BGI Genomics Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yiling Chen | Guosen Securities Co., Ltd. |
| Hanqing Zhu | Guosen Securities Co., Ltd. |
| Jiaxi Xu | Industrial Securities Co. Ltd. |